Antimicrobial resistance (AMR) in Rwanda

AMR is a growing global issue and internationally much AMR research and innovative work goes on. Following the success of the Innovative pharmacy solution to antimicrobial resistance in the UK by the Information Design and Architecture combating drug resistant infection (IDAPPS) project at University of Reading, there was an opportunity to explore how this approach could be taken to an international community.

A collaboration between the University of Reading, the University of Rwanda, the Rwanda Community Pharmacists Union (RCPU), the Commonwealth Pharmacists Association (CPA), Design Science and Isomeric was formed to explore how a design led approach to develop a campaign would change behaviours and attitudes towards AMR in Rwanda.

Pharmacy and health care access in Rwanda

Several workshops in Kigali Rwanda were held to better understand how just over 800 registered pharmacists serve a population of approximately 12.5million and dispense AMR advice. The broader insights of how doctors and community health workers support the community was imperative to ensure any campaign woudl bridge the gap and provide continuity of health care. The project team included designers, behavioural change consultants and pharmacists.

Workshops in Rwanda

The workshops were designed to engage with pharmacist, pharmacy users and other stakeholders. New models that fuelled creativity were introduced at the workshops led by designers and pharmacists. The co-design workshops were practical and interactive and the team came away with many ideas to progress within the context and constraints that were discussed.

• 

• 

• 

Pilot study and pharmacist training

Initial pharmacy materials and a training plan were implemented, during this first phase, across several pharmacies reaching different populations.

The next phase…

Following the success of the pilot phase the project team are developing the materials for a bigger launch reaching a wider population.
Analysis of pilot data, other research in Rwanda and a final workshop in the UK has led to more collaborations and new ideas.

Antimicrobial resistance (AMR)

The overuse and misuse of antibiotics has led to a growing number of antibiotic resistant bacteria in humans.  Antibiotics are life saving medicines and changing attitudes and behaviours in AMR is fundamental in preserving the value they bring to our lives. The pharmacy environment provides an excellent opportunity to improve the knowledge and understanding of antimicrobial resistance.

Changing attitudes and behaviour in AMR

The Arts and Humanities Research Council (AHRC) funded Information Design and Architecture combating drug resistant infection (IDAPPS). IDDAPS is an inter-disciplinary project bringing together academics and practitioners in graphic and information design, architecture, ergonomics and human factors and pharmacy to consider how to ‘improve the knowledge and understanding of antimicrobial resistance’.

Designing persuasive pharmacy space

Design Science and partners developed the winning Beat Bad Bugs (BBB) campaign for IDAPPS. The BBB team are life-size characters each offering a perspective on antibiotic usage. This innovative approach also included various materials to support the pharmacy team at Day Lewis Reading branch.

• 

• 

• 

• 

The approach has been developed and tailored for pharmacies in other countries.

Multiple sclerosis (MS) is a chronic disease attacking the central nervous system (brain and spinal cord) affecting over 2.3million people worldwide, it is 2-3 times more common in women than in men, and people are usually diagnosed between 20 and 50 years of age. Presently, there is no cure for MS, however disease modifying treatments (DMTs) effectively delay disability for people living with MS.

There is extensive information about how people with MS interact with their neurologists and the MS symptoms that they find most distressing. Fatigue is a widespread concern for patients, the significance of which is not always fully understood by those providing medical care and or social support. There is also evidence that the use of medicines may be delayed or impaired because of fears about factors such as drug side effects and or a lack of belief in their benefits.

Why do treatment priorities of peple with MS matter?

There is evidence that the use of medicines may be delayed or impaired because of fears about factors such as drug side effects and or a lack of belief in their benefits. Patients both prioritise and expect treatments that support them in becoming more independent. therfore it is crucial to communicate MS therapeutic advances with patients and instil trust in bio-pharmaceutical innovation, regardless of cultural disparities in attitudes to healthcare. Not much is known about how best such problems can be addressed and the priorities that people with MS have for future treatment improvements.

How was the TaP-MS research conducted?

The aims of he research where to to explore MS patient understandings, beliefs and preferences, to address the gap in present knowledge on expectations and priorities for people with MS and to improve care standards and health outcomes for people with MS globally.

Methodology overview

What did this research achieve?

The main recomenations of the research where

• Understanding concerns about treatment trade-off and how these interplay with individual disease-specific, as well as contextual factors
• Removing barriers to disease comprehension becasue patient perceptions and priorities around the disease and treatment may not accurately be reflected in communications using concepts such as brain health
• Look for a holistic approach when supporting people with MS by providing psychological support

The full report is available to download